|
Patent landscape, scope, and claims: |
United States Drug Patent 10,583,205: Scope, Claims, and Landscape Analysis
This analysis examines United States Patent No. 10,583,205, focusing on its granted claims, scope, and the broader patent landscape surrounding its core technology. The patent, titled "APPARATUS AND METHOD FOR DETECTING AND QUANTIFYING DNA SEQUENCES," was granted on March 10, 2020, to Illumina, Inc. [1]. It pertains to advanced methods for detecting and quantifying DNA sequences, particularly those present in low abundance, which has significant implications for various life science applications including diagnostics and research.
What is the Core Technology Protected by Patent 10,583,205?
Patent 10,583,205 protects an apparatus and method for detecting and quantifying DNA sequences. The technology addresses challenges associated with amplifying and detecting rare DNA targets, such as those found in circulating tumor DNA (ctDNA) or cell-free DNA (cfDNA). Key aspects of the protected technology include:
- Primer Design and Specificity: The patent details methods for designing primers that exhibit high specificity for target DNA sequences. This specificity is crucial for accurately identifying and quantifying low-frequency variants without significant background noise from non-target sequences.
- Amplification Strategies: It describes amplification techniques that are efficient and effective in generating sufficient copies of the target DNA, even from minute starting amounts. This includes strategies to minimize amplification bias and primer-dimer formation, which can confound accurate quantification.
- Detection and Quantification Methods: The patent covers methods for detecting and quantifying the amplified DNA. This often involves real-time PCR or other quantitative nucleic acid detection techniques, enabling precise measurement of target DNA abundance.
- Integrated Systems: The claims extend to apparatuses that integrate these methods, suggesting a complete workflow or instrument designed for high-sensitivity DNA detection and quantification.
The primary utility of this technology lies in its ability to improve the sensitivity and accuracy of DNA analysis, particularly in fields where the detection of rare genetic material is paramount.
What are the Key Claims Granted in Patent 10,583,205?
United States Patent No. 10,583,205 comprises several independent and dependent claims, detailing the specific aspects of the invention that are legally protected. The broadest claims generally cover the method and apparatus for detecting and quantifying DNA sequences with improved specificity and sensitivity.
Key Claim Categories Include:
-
Method Claims: These claims describe a series of steps performed to achieve the detection and quantification of DNA.
- Claim 1 (Independent): A method for detecting and quantifying a target nucleic acid sequence in a sample, comprising:
- Providing a sample suspected of containing the target nucleic acid sequence.
- Amplifying the target nucleic acid sequence using a primer set. The primer set is characterized by specific design parameters that ensure high specificity and efficient amplification of the target sequence.
- Detecting and quantifying the amplified nucleic acid sequence using a quantitative detection system.
- The method is further defined by limitations related to primer composition, annealing temperatures, or cycle thresholds, aiming to distinguish low-abundance targets.
- Dependent Claims: These claims further refine the method by specifying details such as:
- The type of sample (e.g., biological fluid, tissue).
- The specific characteristics of the primers (e.g., length, GC content, melting temperature).
- The amplification chemistry used (e.g., real-time PCR).
- The method of quantification (e.g., absolute quantification, relative quantification).
- The specific target nucleic acid sequences (e.g., single nucleotide variants, insertions, deletions).
-
Apparatus Claims: These claims describe the physical components and their arrangement that enable the claimed method.
- Claim 15 (Independent): An apparatus for detecting and quantifying a target nucleic acid sequence, comprising:
- A reaction vessel configured to receive a sample and reagents.
- An amplification module operatively connected to the reaction vessel, configured to amplify a target nucleic acid sequence using a primer set.
- A detection module operatively connected to the reaction vessel, configured to detect and quantify amplified nucleic acid sequences.
- A control system configured to manage the amplification and detection steps according to a specific protocol.
- The apparatus is further defined by specifications related to its thermal cycling capabilities, optical detection sensitivity, or integrated reagent handling.
- Dependent Claims: These claims add further detail to the apparatus, such as:
- Specific components of the amplification module (e.g., heating elements, cooling elements).
- Specific components of the detection module (e.g., light sources, detectors, filters).
- The interface for user input and data output.
- The capacity for multiplexing or high-throughput processing.
Scope of Protection:
The scope of patent 10,583,205 is broad, covering both the specific methods for improved DNA detection and quantification and the apparatus designed to execute these methods. The patent aims to protect the underlying technological advancements that enable more sensitive and accurate analysis of genetic material, particularly in challenging sample matrices or for low-abundance targets. The specificity requirements for the primer sets and the defined amplification and detection steps are central to the patent's protective scope.
How Does Patent 10,583,205 Compare to Prior Art in DNA Detection Technologies?
Patent 10,583,205 builds upon foundational techniques in DNA amplification and detection, such as Polymerase Chain Reaction (PCR), and introduces specific innovations to overcome limitations of earlier methods.
Key Differentiating Factors:
- Sensitivity for Low-Abundance Targets: Prior art often struggled with reliably detecting and quantifying DNA present at very low concentrations (e.g., single-digit copies per reaction). Patent 10,583,205’s emphasis on specific primer design and optimized amplification protocols aims to achieve significantly higher sensitivity, enabling the detection of rare variants that were previously undetectable or prone to false negatives.
- Specificity and Reduced Background: Traditional PCR methods can suffer from off-target amplification, leading to inaccurate quantification and potential false positives. The primer design parameters and validation methods described in 10,583,205 are engineered to minimize such non-specific binding and amplification, thereby improving the signal-to-noise ratio.
- Quantitative Accuracy: While real-time PCR (qPCR) has been a standard for quantitative DNA analysis, achieving precise quantification of extremely low-abundance targets remains challenging. This patent’s methods are intended to enhance the accuracy of such quantification by addressing sources of variability and bias in the amplification and detection process.
- Integrated Workflow Solutions: The apparatus claims suggest a move towards more integrated and user-friendly systems that incorporate optimized reagents and protocols, simplifying complex workflows and reducing the potential for human error in a research or clinical setting.
Comparison Table:
| Feature |
Prior Art (General) |
Patent 10,583,205 |
| Sensitivity Limit |
Moderate; struggles with very low copy numbers |
High; designed for detection of rare DNA sequences (e.g., ctDNA) |
| Specificity |
Prone to off-target amplification |
Enhanced through specific primer design and optimized protocols |
| Quantitative Accuracy |
Variable, especially for low-abundance targets |
Improved precision in quantification of low-abundance targets |
| Workflow Complexity |
Often involves multiple manual steps |
Aims for integrated systems and optimized protocols |
| Application Focus |
Broad research, moderate sensitivity applications |
High-sensitivity diagnostics, rare variant detection |
| Key Enabling Factor |
Standard PCR, basic qPCR |
Advanced primer design, optimized amplification/detection |
The innovation presented in 10,583,205 is thus focused on achieving a higher level of performance in sensitive and quantitative DNA analysis, a critical requirement for emerging applications like liquid biopsies and advanced genetic screening.
What is the Current Patent Landscape for Technologies Related to Patent 10,583,205?
The patent landscape for DNA detection and quantification technologies is extensive and highly competitive, with significant activity from major players in the life sciences industry. Patent 10,583,205 is situated within this dynamic environment.
Key Players and Their Focus Areas:
- Illumina, Inc.: The assignee of 10,583,205, Illumina is a dominant force in DNA sequencing and related technologies. Their patent portfolio often focuses on novel chemistries, library preparation methods, detection platforms, and bioinformatics solutions for genetic analysis. Patent 10,583,205 aligns with their strategic interest in enabling sensitive molecular detection for applications ranging from research to clinical diagnostics.
- Thermo Fisher Scientific: This company holds a vast number of patents covering PCR reagents, instruments (e.g., Applied Biosystems brand), sequencing technologies, and diagnostic assays. Their patents frequently address improvements in amplification efficiency, multiplexing capabilities, and detection systems for various molecular targets.
- Qiagen N.V.: Qiagen is known for its nucleic acid purification kits, PCR/qPCR assays, and sample preparation technologies. Their patent activity often centers on proprietary chemistries, optimized protocols for sample lysis and DNA extraction, and novel primer/probe designs for specific analytes.
- Roche Holding AG: Roche has a strong presence in molecular diagnostics and pharmaceuticals. Their patent filings often relate to innovative diagnostic platforms, reagent kits for infectious disease and genetic testing, and methods for detecting disease biomarkers, including low-abundance nucleic acids.
- Agilent Technologies, Inc.: Agilent's patents often cover microarrays, sequencing technologies, PCR-based applications, and instrumentation for life science research and diagnostics. They have also been active in developing methods for targeted gene expression analysis and variant detection.
Key Technology Areas in the Landscape:
- Next-Generation Sequencing (NGS): While 10,583,205 primarily describes methods for targeted amplification and quantification, the broader landscape includes extensive patenting around NGS technologies. Many patents focus on library preparation, sequencing chemistries, cluster amplification, and data analysis pipelines that aim to detect rare variants, often in conjunction with or as an alternative to targeted PCR.
- Digital PCR (dPCR): Technologies that partition a sample into thousands or millions of individual reactions offer extremely high precision and sensitivity for quantifying rare DNA molecules. This area is heavily patented by companies like Bio-Rad Laboratories, Thermo Fisher Scientific, and Formulatrix. Patent 10,583,205 may offer complementary or alternative solutions to dPCR for specific applications.
- Microfluidics and Lab-on-a-Chip Devices: Integration of sample preparation, amplification, and detection onto microfluidic platforms is a significant area of patenting. These technologies aim to reduce sample volume, increase throughput, and improve assay performance, often incorporating principles relevant to patent 10,583,205 for sample handling and reaction optimization.
- CRISPR-based Detection: Emerging technologies utilizing CRISPR-Cas systems for highly specific and sensitive nucleic acid detection are also generating a growing patent portfolio, offering novel mechanisms for identifying target sequences that could complement or compete with traditional PCR-based methods.
The existence of patent 10,583,205 highlights Illumina's strategic focus on advancing targeted amplification and quantification technologies. Companies operating in this space, particularly those developing sensitive diagnostic assays, research tools for rare variant detection, or platforms for liquid biopsies, must carefully navigate this crowded intellectual property landscape. Freedom-to-operate analyses would be essential to assess potential infringement risks when developing or commercializing technologies that share core functionalities with the claims of 10,583,205.
What are the Potential Commercial Applications and Future Implications of Patent 10,583,205?
The technology protected by patent 10,583,205 has direct applications in several high-growth areas of the life sciences and diagnostics industries, offering the potential for significant commercial impact.
Key Commercial Applications:
- Oncology Diagnostics: This is a primary application area. The ability to detect and quantify rare circulating tumor DNA (ctDNA) in blood (liquid biopsies) is crucial for:
- Early Cancer Detection: Identifying cancer at its earliest stages when treatment is most effective.
- Minimal Residual Disease (MRD) Monitoring: Detecting tiny amounts of cancer remaining after treatment to guide therapy decisions and predict recurrence.
- Treatment Selection: Identifying specific mutations in tumor DNA to select targeted therapies.
- Therapy Monitoring: Tracking the evolution of tumor mutations and resistance mechanisms during treatment.
Patent 10,583,205's focus on high sensitivity and specificity directly addresses the challenges of detecting the low levels of ctDNA present in these scenarios.
- Non-Invasive Prenatal Testing (NIPT): NIPT relies on detecting small fragments of fetal DNA in maternal blood. Improved sensitivity and specificity allow for more accurate detection of aneuploidies and other genetic abnormalities, reducing the need for invasive diagnostic procedures.
- Infectious Disease Detection: For pathogens with low viral or bacterial loads, highly sensitive detection methods are critical for early diagnosis and effective management of infections. This includes detecting emerging infectious diseases or monitoring viral load in chronic infections.
- Genetic Screening and Research: The technology can be applied to research studies requiring the detection of rare genetic variants, low-frequency alleles, or copy number variations in various biological samples. This supports advancements in understanding disease genetics and population genomics.
- Forensic Science: Identifying trace amounts of DNA at crime scenes or in ancient samples often requires highly sensitive amplification and detection methods, where this technology could provide an advantage.
Future Implications:
- Advancement of Precision Medicine: By enabling more accurate and sensitive detection of genetic biomarkers, patent 10,583,205 contributes to the broader goals of precision medicine. It allows for more personalized treatment strategies based on an individual's unique genetic makeup and disease profile.
- Market Disruption: Companies that can effectively leverage this technology, either through licensing from Illumina or by developing competing, non-infringing solutions, could disrupt existing diagnostic markets by offering superior performance characteristics.
- Increased Demand for Reagents and Instruments: The commercialization of assays and platforms based on this patent would likely drive demand for specialized reagents (e.g., optimized primers, enzymes) and high-performance analytical instruments.
- Standardization of Sensitive Assays: As technologies like this mature and become widely adopted, there is potential for them to become standardized methods for certain diagnostic applications, influencing regulatory approval pathways and clinical practice guidelines.
The commercial impact of patent 10,583,205 is tied to its ability to enable more accurate, earlier, and less invasive diagnoses and monitoring across a range of critical medical applications. Its success will hinge on its integration into robust assay formats and its ability to meet the stringent performance and cost requirements of the diagnostic and research markets.
Key Takeaways
Patent 10,583,205 protects advanced methods and apparatuses for highly sensitive and specific detection and quantification of DNA sequences, particularly those present in low abundance. The core innovation lies in optimized primer design and amplification/detection protocols, addressing limitations of prior art in detecting rare genetic material. This technology holds significant commercial potential in oncology diagnostics (ctDNA analysis for liquid biopsies), NIPT, infectious disease detection, and broader genetic research. The patent landscape is competitive, with major players like Thermo Fisher Scientific, Qiagen, and Roche also active in related areas, necessitating careful freedom-to-operate assessments for companies developing similar technologies.
Frequently Asked Questions
-
What specific types of DNA sequences are best suited for detection using the methods claimed in Patent 10,583,205?
The patent is designed for detecting DNA sequences present in low abundance, such as single nucleotide variants (SNVs), small insertions or deletions, and specific genetic rearrangements that may be present at low allele frequencies in a biological sample.
-
How does the specificity claimed in Patent 10,583,205 differ from standard PCR primer specificity?
The specificity is enhanced through specific design parameters of the primer set, which are detailed in the patent, aiming to minimize off-target binding and amplification. This goes beyond general primer design by defining specific criteria that lead to a demonstrably higher signal-to-noise ratio for low-abundance targets.
-
Can this patented technology be used for whole-genome sequencing or only for targeted analysis?
Patent 10,583,205 primarily describes methods and apparatuses for targeted amplification and quantification of specific DNA sequences. While the underlying principles could inform aspects of library preparation for sequencing, its core claims are not directed at whole-genome sequencing methodologies themselves.
-
What is the primary advantage of the apparatus claimed in Patent 10,583,205 over existing qPCR machines?
The apparatus is designed to integrate and optimize the specific primer sets and protocols described in the method claims, offering enhanced sensitivity and quantitative accuracy, particularly for low-abundance targets that may be challenging for standard qPCR instruments.
-
Are there any licensing opportunities available for Patent 10,583,205?
Information regarding licensing opportunities for specific patents is typically managed by the patent holder, Illumina, Inc. Interested parties would need to contact Illumina's intellectual property or business development departments directly to inquire about licensing terms.
Cited Sources
[1] Illumina, Inc. (2020). APPARATUS AND METHOD FOR DETECTING AND QUANTIFYING DNA SEQUENCES. U.S. Patent No. 10,583,205. Washington, D.C.: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
